Among 872 hospitalized adults aged ≥65 in Italy's Report-AGE cohort, shorter-than-expected leukocyte telomere length — expressed as age-adjusted residuals rather than raw measurements — independently predicted all-cause mortality over a median 10.6-year follow-up. Patients whose telomeres fell below an optimized cut-point faced a 30% higher adjusted mortality hazard (HR=1.30, 95% CI 1.05–1.60), even after controlling for comorbidity burden, polypharmacy, and laboratory parameters. Critically, this association was significant only among non-frail patients, suggesting frailty may override or obscure telomere-linked biological signaling.
The age-adjustment methodology here is the study's most technically meaningful contribution. Raw telomere length conflates biological age with chronological age; expressing LTL as residuals from a reference population isolates accelerated biological aging — a subtle but important refinement. The frailty interaction finding is particularly provocative: it implies telomere biology captures a distinct dimension of aging vulnerability that frailty indexes miss or subsume. This aligns with emerging thinking that biological age clocks and clinical frailty measures tap different, partially overlapping axes of aging.
Limitations are real: this is observational, single-institution, and the modest per-SD hazard ratio (1.10) suggests modest individual predictive power. However, the 82% mortality rate over follow-up and large prospective cohort lend statistical credibility. For clinicians and longevity researchers, this is confirmatory-plus — validating telomere length as a prognostic tool while adding actionable nuance about where it matters most.